Peptide library

BPC-157 claims and the evidence:
what studies measured

BPC-157 is a synthetic peptide of 15 amino acids. For each area its research covers: the model, the sample, what was measured, and the questions the studies leave open. Dated 21 November 2026.

Short answerCompound research · 7 min read · Updated 21 Nov 2026

BPC-157 is a synthetic peptide of 15 amino acids, and the claims about it rest mostly on animal and cell studies: a 2025 systematic review of musculoskeletal research found 35 of its 36 included studies were preclinical. In people, the only randomised data are conference abstracts, and a 2026 systematic review rated the certainty of the human evidence “very low”.

Key takeaways

  • Most BPC-157 research is in animals and cells: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical, and 6AM Research grades its evidence Preclinical.
  • The rat tendon and muscle studies measured walking function, the load tissue held before failing, and tissue under the microscope; most come from one research group, and none is evidence of an effect in people.
  • We found six small published studies that gave BPC-157 to people, most without a control group; the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005 (PubMed and FDA’s 2026 review, 21 Nov 2026).
  • A 2026 systematic review rated the certainty of the human evidence “very low”, and FDA staff found “insufficient clinical safety information to characterize the safety profile”.
  • ClinicalTrials.gov lists four records that give BPC-157; none had posted results on 21 November 2026, and a placebo-controlled phase 2 trial is recruiting.

01BPC-157 claims at a glance: how far the research has gone

How far the research on BPC-157 has gone, dated 21 November 2026. 6AM Research grades its evidence Preclinical on the BPC-157 guide, because most of it sits in animals and cells.

Cell studies
Extensive
Animal studies
Extensive
Studies in people, no control group
4 small studies
Randomised data in people
2, abstracts only
Peer-reviewed randomised trial in people
None found

Bar lengths show order only, not a score, and a row with no qualifying study is drawn at 0%. The rows on people count the six published studies we found that gave BPC-157 to people: four without a control group, and two randomised studies known only from conference abstracts.

Source: Vasireddi et al., HSS J, 2025; FDA’s 2026 review of BPC-157; PubMed and ClinicalTrials.gov searches of 21 Nov 2026.

02What did the main BPC-157 animal and cell studies measure?

If you searched “bpc 157 benefits”, the plain version is this: the studies behind the claims measured specific things, mostly in rats. Three kinds of study, and the model each used; each card names what was measured, not what to expect.

Rats · 2003 · T3

Achilles tendon cut in rats

Walking function, scored daily, and up to day 14 the load the tendon held before failing and its tissue under the microscope. The abstract gives no number of rats.

Rats · 2006 · T3

Thigh muscle cut in rats

Over 72 days: the load the muscle held before failing, walking and motor function, and its tissue under the microscope.

Cells · 2011 · T4

Rat tendon pieces and cells in a dish

How far cells grew out of the tissue, how many survived chemical stress, and how far they moved. A cell result is not evidence of an effect in people.

One research group, mostly. The 2003 and 2006 tendon studies, the 2006 muscle study and a 2008 study of crushed calf muscle all come from the department of pharmacology at the University of Zagreb. Human data on these measures is lacking.

A second group, 2026 (T3). Researchers in Türkiye cut and repaired the Achilles tendon in 32 male rats, eight per group, given BPC-157, TB-500, both or neither. At four weeks they measured the load the tendon held before failing and scored the tissue. The authors call it an “exploratory rat model study”.

03Study by study: model, sample, measure, limit

One row per study cited here. Rows name what was measured, not what to expect.

Area and what was measuredStudyModel and nTierLimit
Tendon: walking function, load to failure, tissue under the microscopeStaresinic et al., 2003Rats with a cut Achilles tendon; n not in the abstractT3No measure in people
Tendon to bone: walking function, load to failure, collagen stainingKrivic et al., 2006Rats with the tendon cut from the heel bone; n not in the abstractT3Same group
Muscle: load to failure, walking and motor function, tissueStaresinic et al., 2006Rats with a cut thigh muscle; 72 days; n not in the abstractT3Same group
Muscle: tissue, function, blood enzymesNovinscak et al., 2008Rats with a crushed calf muscle; 14 days; n not in the abstractT3Same group
Tendon cells: outgrowth, survival under stress, migrationChang et al., 2011Rat tendon pieces and tendon cells in cultureT4Cells only; not evidence of an effect in people
Tendon after repair: load to failure, tissue scores, collagen types I and IIIBiçer et al., 202632 male rats, 8 per group: BPC-157, TB-500, both or neither; 4 weeksT3The authors call it exploratory
People, healthy volunteers: tolerability, blood levelsVeljaca et al., 2002 and 200332 randomised, 24 given BPC-157, the rest placeboT2Conference abstracts only, summarised by FDA staff
People, patients: among the measures, a disease-activity score and blood levelsRuenzi et al., 200553 randomised to BPC-157 or placebo, 46 completedT2Conference abstract only; FDA staff found the data inadequate

T2 is small or uncontrolled human research, T3 is animal studies and T4 is cell studies: how we grade evidence. The two abstract-only studies are known from FDA’s 2026 review. Material sold online is not the product these studies tested.

04Has BPC-157 been tested in people?

In small studies, and not in a peer-reviewed randomised trial (PubMed, 21 November 2026). In the published literature we found six studies that gave BPC-157 to people, 118 participants in all. Reports made to FDA are a separate record; they show no cause and no rate.

  1. 2002–2003Healthy-volunteer abstracts

    Conference abstracts, summarised by FDA staff, describe a randomised, placebo-controlled study in 32 healthy volunteers that measured tolerability and blood levels.

  2. 2005A patient study, abstract only

    A randomised, placebo-controlled study of 53 patients, 46 of whom completed it. FDA staff found its data “inadequate to support the efficacy and safety” of BPC-157 in that setting.

  3. 2021–2025Three small studies without a control group

    A chart review with a phone survey of 16 patients (2021), a single-arm study of 12 women (2024) and a two-person safety pilot (2025). All three list the same first author.

  4. Sep 2026A three-patient case report

    Three patients received BPC-157 together with TB-500 and other agents, with no control group. The authors write that causality “cannot be established”.

  5. 2026A systematic review

    Reviewing the three full papers, 30 people in all, the authors judged each of poor methodological quality and rated the certainty of the evidence “very low”.

  6. Nov 2026Registered, no results

    ClinicalTrials.gov lists four records that give BPC-157, none with posted results. One, NCT07437547, is a placebo-controlled phase 2 trial planned for 120 patients aged 18 to 45, recruiting since February 2026.

The phase 2 trial asks whether time to return to sport, and the size of a muscle injury on MRI, differ from placebo. Every study, with its design and size: BPC-157 human studies.

05What did FDA staff and independent reviewers conclude?

FDA, on effectiveness. Reviewing BPC-157 for the list of substances pharmacies may compound with, FDA staff found “a lack of evidence to support the effectiveness” of BPC-157 for the use nominated to them. In a search of globalEDGE they found it in no approved product in any country.

FDA, on animal studies. FDA staff noted that rat studies have reported effects of BPC-157-related substances in models of induced gut, liver and fistula injury. They added that the relationship between amount and response has “not been established”, that the molecular targets “have not been identified” and that the mechanisms “remain poorly understood”, so the plausibility of those effects is “difficult to assess”. They judged the animal toxicity studies “too limited in scope and duration” to inform safety.

FDA, on safety in people. FDA staff concluded that there is “insufficient clinical safety information to characterize the safety profile” of BPC-157.

Independent reviews. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons, searching to June 2026, found the human musculoskeletal evidence “limited to one small retrospective uncontrolled case series without validated outcome measures”, and no “controlled human orthopaedic efficacy evidence” for BPC-157, thymosin β4 or TB-500.

Where BPC-157 stands with regulators in the US, UK and Australia, and in sport: the BPC-157 guide. What has been reported about adverse events: BPC-157 side effects.

06What we don’t know about BPC-157

Whether any effect shows up in people

We found no peer-reviewed randomised trial of BPC-157 in people (PubMed, 21 Nov 2026), and the four registered studies have posted no results.

Whether rat results carry over

Most tendon and muscle studies come from one group, in rats. FDA staff write that the link between amount and response has not been established, and that the molecular targets have not been identified.

How the body handles it

In the two studies that measured blood levels, FDA staff report that BPC-157 was not detected, or mostly below the assay’s limit. Both are known only from conference abstracts.

Which molecule a vial holds

FDA gives BPC-157 free base a molecular weight of 1419.5 g/mol. The mass result on a lot’s report is the line that shows whether a sample matches.

How to find that line on a lab report: how to read a COA. How a mass result identifies a peptide: mass spectrometry explained.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 13, 24, 27, 29, 32, 40, 42–43, 46, 53–54); downloaded and read 21 Nov 2026 (SHA-1 253cd664…). www.fda.gov/media/193343/download
  2. Vasireddi N, Hahamyan H, Salata MJ, et al. [Systematic review of BPC-157 musculoskeletal research.] HSS J, 2025;21(4):485–495. PMID 40756949; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/40756949/
  3. Staresinic M, Sebecic B, Patrlj L, et al. [Rat Achilles tendon transection study, with cultured tendon cells.] J Orthop Res, 2003;21(6):976–983. PMID 14554208; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/14554208/
  4. Krivic A, Anic T, Seiwerth S, et al. [Rat Achilles tendon-to-bone detachment study.] J Orthop Res, 2006;24(5):982–989. PMID 16583442; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/16583442/
  5. Staresinic M, Petrovic I, Novinscak T, et al. [Rat quadriceps transection study.] J Orthop Res, 2006;24(5):1109–1117. PMID 16609979; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/16609979/
  6. Novinscak T, Brcic L, Staresinic M, et al. [Rat gastrocnemius crush study.] Surg Today, 2008;38(8):716–725. PMID 18668315; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/18668315/
  7. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. [Rat tendon explants and cultured tendon fibroblasts: outgrowth, survival and migration.] J Appl Physiol, 2011;110(3):774–780. PMID 21030672; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/21030672/
  8. Biçer O, Adanir O, Güleryüz Y, et al. [BPC-157 and TB-500 in rats after Achilles tendon transection and repair.] Jt Dis Relat Surg, 2026;37(3):822–837. PMID 42542926; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42542926/
  9. Lee E, Padgett B. [Retrospective chart review of 17 patients given BPC-157, alone or with thymosin β4.] Altern Ther Health Med, 2021;27(4):8–13. PMID 34324435; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/34324435/
  10. Lee E, Walker C, Ayadi B. [Single-arm pilot study of BPC-157 in 12 women.] Altern Ther Health Med, 2024;30(10):12–17. PMID 39325560; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/39325560/
  11. Lee E, Burgess K. [Two-person pilot safety study of BPC-157.] Altern Ther Health Med, 2025;31(5):20–24. PMID 40131143; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/40131143/
  12. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several peptides and other agents.] Front Oral Health, 2026;7:1907109. PMID 42876687; full text PMC13661421 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42876687/
  13. Poolton JT, Minett J, Kazmi A. [Systematic review of human studies of BPC-157, with GRADE certainty ratings.] Acta Orthop Belg, 2026;92(3). PMID 42885452; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42885452/
  14. Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg, 2026, online 27 Oct. PMID 42937313; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42937313/
  15. ClinicalTrials.gov. NCT02637284, NCT07752381, NCT07437547 and NCT07803250 (searches for BPC-157, BPC 157, BPC157, pentadecapeptide, bepecin, PL 14736): status, design and posted-results field of each. PubMed search the same day: BPC-157 name set in title or abstract, 240 records; with randomised, clinical or controlled trial publication types, 0. API v2 and E-utilities, 21 Nov 2026. clinicaltrials.gov/study/NCT07437547

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

What do the claims about BPC-157 rest on?

Mostly on animal and cell studies: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical. In people we found six small published studies, and the only randomised data are conference abstracts.

Has BPC-157 been tested in humans?

In small studies only. We found six published studies that gave it to people, 118 participants in all, most without a control group, and no peer-reviewed randomised trial (PubMed, 21 Nov 2026); the four registered studies have posted no results.

What did the 2003 rat tendon study measure?

In rats whose Achilles tendon was cut, it scored walking function daily and, up to day 14, tested the load the tendon held before failing and looked at the tissue under the microscope. It is an animal result; human data on this is lacking.

Why do FDA staff say the animal findings are hard to interpret?

In their 2026 review they wrote that the link between amount and response has not been established, the molecular targets have not been identified and the mechanisms of action remain poorly understood.

Where does BPC-157 stand with regulators?

Drugs@FDA lists no product containing it, and FDA staff found it in no approved product in any country they searched. WADA names it in class S0, prohibited at all times. Status by country is on the BPC-157 guide.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page